

# Systematic review of survey/questionnaire-based drug utilization studies in Turkiye

# Onur Gultekin,<sup>1</sup> Nazim Haspolat,<sup>2</sup> Bahar Cicek,<sup>1</sup> Dieudonné Havyarimana,<sup>1</sup> Ahmet Akici,<sup>1</sup> Volkan Aydin<sup>3</sup>

<sup>1</sup>Department of Medical Pharmacology, Marmara University Faculty of Medicine, Istanbul, Turkiye <sup>2</sup>Department of Medical Pharmacology, Uludag University Faculty of Medicine, Bursa, Turkiye <sup>3</sup>Department of Medical Pharmacology, Medipol University Faculty of Medicine, Istanbul, Turkiye

# ABSTRACT

**OBJECTIVE:** Drug utilization studies (DUS), providing insights into various aspects of pharmacoepidemiology from prescribing to medication use, can be conducted through real-world data from health records and survey-based data. In this study, we aimed to describe survey/questionnaire-based DUS conducted in Turkiye.

**METHODS:** We searched online databases for the most frequently used keywords in DUS from January 1993 till May 2023 and identified 180 survey-based DUS conducted in Turkiye. We described DUS by their populations, sociodemographic characteristics, timeframe, setting and provinces, data collection method, medication categories, and article-specific variables were evaluated.

**RESULTS:** We identified that 68.3% of the DUS were in English and 91.7% were indexed in Web of Science (median 1 [interquartile range: 1-2] citation). We found that 21.7% of the articles (n=39) had pharmacology affiliation. Adults are the target population in 37.8% of the studies and age and gender were not reported in 27.2% and 16.7%, respectively. The response rate was not stated in 55.0%. We determined that 48.3% of the studies were focused on a single medication/medication group. The mean time from data collection to publication was 2.5±1.9 years, and the highest number of articles (10.6%) were published in 2021.

**CONCLUSION:** Our systematic review shows that the majority of DUS were listed in well-known international indices, suggesting that our local studies invoke global interest and hold a valuable position in health research. Nevertheless, lack of reporting of methodological characteristics in substantial part of the studies can be considered an important room for improvement of DUS.

Keywords: Drug utilization studies; pharmacoepidemiology; questionnaire; survey; systematic review.

*Cite this article as:* Gultekin O, Haspolat N, Cicek B, Havyarimana D, Akici A, Aydin V. Systematic review of survey/questionnaire-based drug utilization studies in Turkiye. North Clin Istanb 2024;11(6):000–000.

Drug utilization studies (DUS) is a versatile scientific discipline that combines descriptive and analytical methods, enabling the evaluation of medical, social, and economic aspects of the prescription, distribution, and consumption processes of drugs [1-3]. DUS also facilitate the testing of interventions aimed at improving quality in these areas [2]. DUS encompasses the assessment of the current state of drug utilization, future trends, drug expenditures, disease prevalence, and the rationality of prescriptions. Being a valuable research field in pharmacoepidemiology, it also serves as a bridge with other health-related disciplines [4]. Therefore, enhancing DUS is considered a priority at both national and international levels [5].



Received:January 03, 2024Revised:April 08, 2024Accepted:May 14, 2024Online:November 22, 2024Correspondence:Volkan AYDIN, MD.Istanbul Medipol Universitesi Tip Fakultesi, Tibbi Farmakoloji Anabilim Dali, Istanbul, Turkiye.Tel:+90 216 444 85 44e-mail:volkanaydin@gmail.comIstanbul Provincial Directorate of Health - Available online at www.northclinist.com

Survey and questionnaire usage are frequently employed in academic studies as well as various practical applications in fields such as health and education. It is well known that DUS also extensively benefits from these methods [6]. With the widespread adoption of electronic databases today, the evaluation of data related to the process from prescribing to the usage of medications in DUS has become more functional and comprehensive. Besides, the offering of real-world data on drug utilization, coupled with the development of information technologies, makes survey methods even more valuable for DUS, enabling large-scale surveys to be conducted [3, 7]. However, the scarce number of articles examining DUS in Turkiye did not seem to provide a review about survey- or questionnaire-based DUS, focusing merely on particular aspects of the drug utilization [3, 8, 9]. In this study, we aimed to describe survey/questionnaire-based DUS conducted in Turkiye.

## MATERIALS AND METHODS

After approval by the Istanbul Medipol University Non-interventional Clinical Research Ethics Committee (approval no: 11.05.2023-429), in line with the principles of the Declaration of Helsinki, we collected the data from online article databases for the studies published between January 1, 1993, and April 30, 2023. We considered an article as eligible provided that it described an original research study, used survey data related to the drug utilization, and was accessible in English or Turkish full text. We analyzed the parameters related to the population to which surveys were directed and their sociodemographic characteristics, the timeframe of the study, the setting and cities where the surveys were conducted, the data collection method, the presence of scale usage, the investigated drug categories, as well as the qualities of the articles and the journals in which they were published. We referred to the current PRISMA checklist and flowchart during the data collection process in the study [10].

In line with the objectives of this systematic review, we conducted a search using keywords through internet access between May 5, 2023, and May 15, 2023. As a result of this screening, survey-based DUS published during the study period were accessed. In this context, keywords commonly encountered in DUS published worldwide and in Turkiye were identified [3, 11, 12]. The following keywords, detailed below,

#### **Highlight key points**

- The vast majority of the survey-based drug utilization studies were published in the journals of the Web of Science.
- The reporting of key methodological characteristics was lacking in a substantial number of studies.
- A number of content- and methodology-related factors were associated with the likelihood of publication in recognized indexes.
- Antibiotics constituted one-third of the medication groups surveyed.

were searched in both Turkish and English through the PubMed, ScienceDirect, Google Scholar, Web of Science (WoS), SCOPUS, and the National Academic Network and Information Center search engines. We identified 180 original research articles, accessible in English or Turkish full text, using survey data related to the DUS conducted in Turkiye and included in this review.

The searched keywords were as follows: subgroups of healthcare centers (hospital, primary care, secondary care, pharmacy, etc.), subgroups of healthcare professions (physician, dentist, pharmacist, nurse, midwife, health technician, etc.), specific patient groups (pediatrics, geriatrics, pregnancy, etc.), commonly encountered acute and chronic diseases (upper respiratory tract infection, urinary tract infection, depression, asthma, hypertension, diabetes, etc.), commonly encountered symptoms (fever, nausea, diarrhea, etc.), medications and medication groups commonly used in the treatment of diseases and symptoms (chemotherapeutics, statins, anticoagulants, diuretics, mucolytics, antacids, etc.), the words related to surveys and survey techniques (questionnaire, survey, etc.), words related to the rationality of drug use (rational, irrational, etc.), the concepts related to the effectiveness, safety, suitability, and cost of drugs (inappropriate, generic, price, prescription, etc.), the concepts related to specific conditions of drug use (prophylaxis, off-label drug use, polypharmacy, etc.).

In the examinations conducted at the provincial level, the necessary population data were obtained using the country's "Address-Based Population Registration System Data" for the year 2021 [13]. Additionally, we categorized the examined articles into two groups based on the index of the journal where they were published, as "SCIE (Science Citation Index-Expanded)" and "non-SCIE" and then compared them.

#### **Statistical Analysis**

Quantitative data were analyzed using Microsoft Excel 2021 for Windows (Microsoft Corp., Redmond, WA, USA) and IBM SPSS Statistics for Windows 22.0 (IBM Corp., Armonk, NY, USA). The data were expressed as numbers and percentages for categorical variables and as mean±standard deviation or median and interquartile range (IQR) for continuous variables. The chi-square test was used for comparisons involving categorical variables. Cases where the Type 1 error value was below 0.05 were considered statistically significant.

## RESULTS

Out of 180 articles, 68.3% were written in English. We accessed 81.1% of these articles from open sources, and 52.8% were published in journals indexed in the SCIE database. We found that 91.7% of the publications were registered in the WoS platform and received a median of 1 (IQR: 1-2) citation. All articles were available on Google Scholar with a median of 2 (IQR: 1-3) citations on this platform. The median number of authors for the articles was 4 (IQR: 1-10), with pharmacology contributions identified in 21.7% (n=39), with two-thirds from medical pharmacology. Ethical committee approval status was declared for 68.3% of the articles (n=123), with 88.6% reporting approval obtained and 11.4% stating that approval was not required. In 59.4% of the publications (n=107), consent for participation in the study was obtained (35.5% not specifying the method of consent acquisition, 36.4% indicating written consent, 25.2% reporting verbal consent, and 2.8% stating both). We further detected that consent was not obtained in 1.7% of the publications, and 38.9% did not provide any information on consent. The presence of sponsorship was not reported in 72.2% of the studies and in 22.2% of the studies, it was stated there was no sponsor. The remaining articles declaring sponsor (5.6%) were supported by various institutions and organizations (60.0%) or pharmaceutical companies (40.0%).

We observed that 51.7% of the studies focused on multiple medication groups, while 87 (48.3%) publications were specifically centered on a single medication or medication group. Among these publications, the highest number of studies were conducted on antibiotics (34.5%), followed by psychopharmacological medications (6.9%), and gastric acid suppressants (5.8%) along with medications for obstructive lung diseases (5.8%).



in provinces with a population exceeding one million.

We identified that 22.1% (n=46) of the studies were stated to be conducted nationwide without specifying the province in Turkiye. Among the studies where the province was declared, the highest frequencies were found in Istanbul (13.0%), Ankara (7.7%), and Izmir (5.8%). The examined studies had an adjusted ranking of 2.1 per one million population in Turkiye, with Samsun having the highest number of studies among provinces with over one million populations (4.4/million people), followed by Ankara (2.8/ million people) and Izmir (2.7/million people), (Fig. 1).

We found that 67.8% of the studies lasted  $\leq 1$  year (8.9% of all studies did not specify the duration of the study). The years 2017 and 2019 had the highest coverage in terms of data collection duration (8.3%). The mean time to publish the study after completion of data collection was 2.5±1.9 years, with the highest number of articles (10.6%, n=19) published in 2021. We observed that 76 publications (42.2%) were published in the last 5 years, with an increasing trend in the number of publications (Fig. 2).

We detected cross-sectional studies as the most preferred design, accounting for 57.8%. In 5.6% of the publications, there was no statement about the study design. The studies were most frequently conducted in healthcare centers (59.4%), followed by those conducted through remote access (12.8%; online or by phone), educational settings (8.9%), home visits (8.3%), and other environments (3.3%). In addition, we noted that the environment where the study was conducted was not specified in 7.2% of the publications.

The target audience was adult population in 37.8% of the studies. The studies were conducted with different age groups in 27.2%, with the elderly in 5.6%, and with chil-

70 of Articles 40 30 20 1993-1997 2008-2012 2013-2017 2018-2023 1998-2002 Years SCI/SCIE - Total FIGURE 2. Distribution of the number of articles by publication years. SCIE: Science citation index-expanded.

dren in 2.2%. More than a quarter of the studies (27.2%) did not report age data. While the gender was not specified in 16.7% of the publications, surveys were conducted exclusively in either women or men in 2.7%, with the remaining (80.6%) covering both male and female participants. We further detected that the predominant gender among audience was women in 69.5% of studies. The majority of individuals surveyed were healthcare professionals (48.6%), followed by the general population (27.6%) and patients (23.8%).

We failed to find a statement regarding the participants' response rate to the questionnaire in 55.0% of the publications. Among those who reported this rate (n=81), the average was 77.4 per hundred participants. Face-to-face interviews constituted the data collection method in 40.8% of the studies, followed by self-administered questionnaire forms (32.6%) and 16.9% through remote access (87.1% online, 12.9% by phone). There was no information about the method of obtaining data in 9.8% of the studies. We determined that in 94.4% of the studies, the data collection process was solely through surveys, while 3.3% included surveys related to interventions (all were educational interventions).

We found that 92.2% of the studies did not include a criterion for assessing whether medication use was rational. In 83.9% of the publications, there was no declaration of using any scale related to the questionnaire. The remaining were detected to use different scales, with one-third of them utilizing Likert scales. We observed that 61.1% of the surveys assessed participants' knowledge, and 69.4% assessed their attitudes.

| Table 1. | Dist | ribution  | of the | e top | 25 | most | freque | ently | used |
|----------|------|-----------|--------|-------|----|------|--------|-------|------|
| keyword  | s in | publicati | ons    |       |    |      |        |       |      |

| Rank | Keywords                        | n   | %     |
|------|---------------------------------|-----|-------|
| 1    | Rational use of drugs           | 37  | 6.8   |
| 2    | Self-medication                 | 13  | 2.4   |
| 3    | Antibiotic                      | 11  | 2.0   |
| 4    | Elderly                         | 10  | 1.8   |
| 5    | Medication                      | 10  | 1.8   |
| 6    | Medication adherence            | 9   | 1.6   |
| 7    | Physician                       | 9   | 1.6   |
| 8    | Survey                          | 8   | 1.5   |
| 9    | Attitude                        | 7   | 1.3   |
| 10   | Knowledge                       | 7   | 1.3   |
| 11   | Nurse                           | 7   | 1.3   |
| 12   | Prescription                    | 7   | 1.3   |
| 13   | Patient                         | 6   | 1.1   |
| 14   | Primary care                    | 6   | 1.1   |
| 15   | Behavior                        | 5   | 0.9   |
| 16   | Drug                            | 5   | 0.9   |
| 17   | Turkiye                         | 5   | 0.9   |
| 18   | Community pharmacy              | 4   | 0.7   |
| 19   | Diabetes                        | 4   | 0.7   |
| 20   | Education                       | 4   | 0.7   |
| 21   | Gastroesophageal reflux disease | 4   | 0.7   |
| 22   | Medication use                  | 4   | 0.7   |
| 23   | Over-the-counter                | 4   | 0.7   |
| 24   | Questionnaire                   | 4   | 0.7   |
| 25   | Antibiotic resistance           | 3   | 0.5   |
|      | Other                           | 354 | 64.7  |
|      | Total                           | 547 | 100.0 |

The mean number of keywords used in the publications was determined to be  $4.1\pm1.5$ , with no keywords in 10 articles (5.6%). Among the total of 547 keywords/keyword groups used in the publications, the most commonly encountered (6.8%) was "rational use of drugs" (Table 1).

We further analyzed the relationship between the characteristics of the publications and the indexing status of the journals they were published in. Accordingly, studies that were in English (p<0.0001), focused on a single drug/drug group (p<0.007), declared the response rate of the survey (p<0.001), declared the sponsorship status of the study (p<0.028), and had more than 4 authors in the publication (p<0.005) were significantly more likely to be published in the journals indexed in the SCIE (Table 2).

TABLE 2. Comparison of the relationship between the characteristics of publications and the indexing status of the journals in which they were published

| Language     Figlish     73.2     76.8     173     0.0001       Turkish     8.8     91.2     73.7     0.0001       Number of examined medication/medication group     63.2     76.8     87     0.0007       Multiple medication groups     63.2     76.8     87     0.0007       Response rate     70     73.3     81     0.001       Not declared     66.7     33.3     81     0.001       Not declared     66.0     34.0     50     0.028       Not declared     66.0     34.0     50     0.028       Not declared     66.7     33.3     104     0.005       Not declared     66.7     33.3     104     0.005       Not declared     66.7     33.3     104     0.005       Environment of four authors     44.7     55.3     114     0.005       Environment of the study conducted in     10     0.81     0.01     0.01       Gener of target audience     10     0.48     16.0     0.01     0.01                            | Characteristics of the published article       | SCIE, n=95 | Non-SCIE, n=85 | Total, n | р      |
|---|--|------------|----------------|----------|--------|
| Énglish     73.2     26.8     123     0.0001       Turkish     8.8     9.12     57       Number of examined medication/medication group     63.2     36.8     87     0.007       Multiple medication/medication group     63.2     36.8     87     0.007       Multiple medication groups     63.0     33.3     81     0.001       Response rate     73.2     130     0.028       Declared     66.0     34.0     50     0.028       Not declared     66.7     33.3     66     0.028       Every and thors     44.7     55.3     114     0.005       Every and thors     66.7     33.3     66     0.00       Every and thors     44.7     55.3     107     0.051       Other environments     67.7     5.3     107   | Language                                       |            |                |          |        |
| Turkish8.891.257Number of examined medication/medication group6.3.23.6.88.70.007Multiple medication/medication group43.057.09393Response rate0.001Declared66.73.3.38.10.001Not declared41.458.699Sponsorship status0.028Declared66.034.0500.028Not declared7.752.3130Number of authors55.31140.005More than four authors66.733.366Environment of the study conducted in </td <td>English</td> <td>73.2</td> <td>26.8</td> <td>123</td> <td>0.0001</td>  | English  | 73.2       | 26.8           | 123      | 0.0001 |
| Number of examined medication/medication group63.236.8870.007Single medication groups43.057.093Response rate77.093Declared66.733.3810.001Not declared66.034.0500.028Sponsorship status72.3130Declared66.034.0500.028Not declared66.034.0500.028Not declared66.735.31140.005More than four authors66.735.31140.005More than four authors66.735.31070.051Cher environment of the study conducted in </td <td>Turkish</td> <td>8.8</td> <td>91.2</td> <td>57</td> <td></td>  | Turkish  | 8.8        | 91.2           | 57       |        |
| Single medication/medication group63.236.8870.007Multiple medication groups63.057.09393Response rate66.733.3810.001Not declared66.733.3810.001Sponsorship status939393Declared66.034.0500.028Not declared66.733.36693Number of authors64.755.31140.005More than four authors64.753.31640.001More than four authors64.752.31070.051Other environment of the study conducted in77.752.31070.051Other environments63.336.7609393Declared94.650.41310.1650.035Not declared61.238.8499494Gender of target audience94.650.41310.165Not declared51.348.71500.385Not declared55.542.5870.222General population/Patients84.451.69393Study design95.547.51620.638Not declared52.644.4189494Declared63.050.01100.395Not declared50.050.01100.395Not declared55.644.41893Declared56.0 <t< td=""><td>Number of examined medication/medication group</td><td></td><td></td><td></td><td></td></t<>  | Number of examined medication/medication group |            |                |          |        |
| Multiple medication groups     43.0     57.0     93       Response rate   | Single medication/medication group             | 63.2       | 36.8           | 87       | 0.007  |
| Response rate     U       Deckared     66.7     33.3     81     0.001       Not declared     41.4     58.6     99       Sponsorship status       200       Declared     66.0     34.0     50     0.028       Not declared     67.7     23.3     100        Number of authors     44.7     55.3     114     0.005       More than four authors     66.7     33.3     66        Environment of the study conducted in           Healthcare related environment     47.7     52.3     107     0.051       Other environments     63.3     36.7     60   <  | Multiple medication groups                     | 43.0       | 57.0           | 93       |        |
| Declared     66.7     33.3     81     0.001       Not declared     41.4     58.6     99       Sponsorship status      50     0.028       Not declared     66.0     34.0     50     0.028       Not declared     47.7     52.3     130        Number of authors     47.7     55.3     144     0.005       More than four authors     66.7     33.3     66        Less than or equal to four authors     66.7     33.3     66        Item antion authors     66.7     33.3     66         Healthcare related environment     47.7     52.3     107     0.051       Other environments     63.3     36.7     60        Age of target audience            Declared     61.3     48.7     150     0.385           Gender of target audience  | Response rate                                  |            |                |          |        |
| Not declared     41.4     58.6     99       Sponsorship status  | Declared                                       | 66.7       | 33.3           | 81       | 0.001  |
| Sponsarship status     Spectared     66.0     34.0     50     0.028       Not declared     47.7     52.3     130       Number of authors     66.7     33.3     66       Eves than or equal to four authors     66.7     33.3     66       Environment of the study colucted in     114     0.005       Environment of the study colucted in     127     52.3     107     0.051       Other environments     63.3     36.7     60     131     0.1051       Declared     99.6     50.4     131     0.1051     0.00     131     0.1051       Declared of target audience     131     68.67     38.8     49     100     100     100     100     100     100     100     100     100     100     100     122     100     100     100     122     100     100     100     100     100     100     120     120     100     120     120     100     120     120     100     120     120     100   | Not declared                                   | 41.4       | 58.6           | 99       |        |
| Declared     66.0     34.0     50     0.028       Number of authors     47.7     52.3     130       Number of authors     44.7     55.3     114     0.005       More than four authors     66.7     33.3     66     0.028       Finvironment of the study conducted in  | Sponsorship status                             |            |                |          |        |
| Not declared     47.7     52.3     130       Number of authors     44.7     55.3     114     0.005       More than four authors     66.7     33.3     66       Environment of the study conducted in     114     0.005       Healthcare related environment     47.7     52.3     107     0.051       Other environments     63.3     36.7     60     201     0.051       Age of target audience     12     38.8     49     0.051     0.055     0.055     0.055     0.  | Declared                                       | 66.0       | 34.0           | 50       | 0.028  |
| Number of authors     44.7     55.3     11.4     0.005       More than four authors     66.7     33.3     66       Environment of the study conducted in  | Not declared                                   | 47.7       | 52.3           | 130      |        |
| Less than or equal to four authors     44.7     55.3     114     0.005       More than four authors     66.7     33.3     66       Environment of the study conducted in     47.7     52.3     107     0.051       Meet the environments     63.3     36.7     60     66       Age of target audience     83.3     36.7     60     66       Declared     49.6     50.4     131     0.165       Not declared     61.2     38.8     49     66       Gender of target audience     91.3     48.7     150     0.385       Not declared     60.0     40.0     30     122       General population//Patients     57.5     42.5     87     0.22       General population//Patients     57.5     42.5     87     0.22       General population//Patients     58.4     16.6     93     123     0.638       Not declared     50.0     10.0     100     0.638     10     0.638       Not declared     58.5     47.5     162                | Number of authors                              |            |                |          |        |
| More than four authors     66.7     33.3     66       Environment of the study conducted in     107     0.051       Healthcare related environment     47.7     52.3     107     0.051       Other environments     63.3     36.7     60     0       Age of target audience     101     0.165     0 <td< td=""><td>Less than or equal to four authors</td><td>44.7</td><td>55.3</td><td>114</td><td>0.005</td></td<>  | Less than or equal to four authors             | 44.7       | 55.3           | 114      | 0.005  |
| Environment of the study conducted in     47.7     52.3     107     0.051       Other environments     63.3     36.7     60       Age of target audience     131     0.165       Declared     61.2     38.8     49       Gender of target audience     100     49.6     50.4     131     0.165       Declared of target audience     102     38.8     49     150     0.385       Ont declared of target audience     101     36.7     150     0.385       Not declared of target audience     100     49.0     30     0.222       General population/Patients     57.5     42.5     87     0.222       General population/Patients     48.4     51.6     93     222       General population/Patients     48.4     51.6     93     222       General population/Patients     89.5     47.5     162     0.638       Not declared     52.6     44.4     18     202     36.8     37       Declared     55.6     44.4     18     31 | More than four authors                         | 66.7       | 33.3           | 66       |        |
| Healthcare related environment     47.7     52.3     107     0.051       Other environments     63.3     36.7     60       Age of target audience          Declared     49.6     50.4     131     0.165       Not declared     61.2     38.8     49        Gender of target audience        0.123     0.385       Not declared     51.3     48.7     150     0.385     0.0385       Not declared     60.0     40.0     30       0.222     General population/Patients     48.4     51.6     93      0.222     General population/Patients     60.0     40.0     10      0.222     General population/Patients     55.5     47.5     162     0.803     Not declared<   | Environment of the study conducted in          |            |                |          |        |
| Other environments     63.3     36.7     60       Age of target audience  | Healthcare related environment                 | 47.7       | 52.3           | 107      | 0.051  |
| Age of target audience   99.6   50.4   131   0.165     Not declared   61.2   38.8   49     Gender of target audience        Declared   51.3   48.7   150   0.385     Not declared   60.0   40.0   30      Target audience          Healthcare professional   57.5   42.5   87   0.222     General population/Patients   48.4   51.6   93      Study design <t< td=""><td>Other environments</td><td>63.3</td><td>36.7</td><td>60</td><td></td></t<>   | Other environments                             | 63.3       | 36.7           | 60       |        |
| Declared     49.6     50.4     131     0.165       Not declared     61.2     38.8     49       Gender of target audience          Declared     51.3     48.7     150     0.385       Not declared     60.0     40.0     30        Target audience          38.8     49.0     30        0.385     Not declared     60.0     40.0     30            38.8     48.4     51.6     93         31.3        30.0        33.8      33.2        33.8      33.2       33.8      30.0     30.0      30.0     30.0      33.0      33.8      33.8      33.2     33.6     35.6     33.0     30.0   | Age of target audience                         |            |                |          |        |
| Not declared     61.2     38.8     49       Gender of target audience     51.3     48.7     150     0.385       Not declared     60.0     40.0     30     30       Target audience      57.5     42.5     87     0.222       General population/Patients     57.5     42.5     87     0.222       General population/Patients     84     51.6     93     222       General population/Patients     84     51.6     93     222       General population/Patients     82.4     47.6     170     0.638       Not declared     60.0     40.0     10     20       Declared     89.5     47.5     162     0.803       Not declared     55.6     44.4     18     20       Obtainment of informed consent     20     70     20     20       Not declared     50.0     50.0     110     0.494       Not declared     62.0     36.8     37     0.52       Obtainment of informed consent     20   | Declared                                       | 49.6       | 50.4           | 131      | 0.165  |
| Gender of target audience     51.3     48.7     150     0.385       Not declared     60.0     40.0     30       Target audience       30       Healthcare professional     57.5     42.5     87     0.222       General population/Patients     48.4     51.6     93        Study design       30      30       Declared     52.4     47.6     170     0.638     30       Not declared     60.0     40.0     10       30      30     30     30      30      33     30     30     30      30      30     30     30     30     33     33     33     33     33     33     33     33     33     33     33     33     33     33     33     33     33     33     33     34     34     34     34     34     34     34     34     34     34<  | Not declared                                   | 61.2       | 38.8           | 49       |        |
| Declared     51.3     48.7     150     0.385       Not declared     60.0     40.0     30       Target audience  | Gender of target audience                      |            |                |          |        |
| Not declared     60.0     40.0     30       Target audience   | Declared                                       | 51.3       | 48.7           | 150      | 0.385  |
| Target audience   F3.5   42.5   87   0.222     General population/Patients   48.4   51.6   93     Study design   52.4   47.6   170   0.638     Not declared   60.0   40.0   10   00     Declared   89.5   47.5   162   0.803     Not declared   55.6   44.4   18   00     Declared   55.6   44.4   18   00     Obtainment of informed consent   55.6   44.4   18   00     Declared   50.0   50.0   110   0.349     Not declared   57.1   42.9   70   00     Approval of ethics committee   00   10   0.349     Not declared   63.2   36.8   57     Pharmacology branch contribution   63.2   36.8   57     Pharmacology branch contribution   52.5   47.5   139   | Not declared                                   | 60.0       | 40.0           | 30       |        |
| Healthcare professional     57.5     42.5     87     0.222       General population/Patients     48.4     51.6     93       Study design  | Target audience                                |            |                |          |        |
| General population/Patients     48.4     51.6     93       Study design   | Healthcare professional                        | 57.5       | 42.5           | 87       | 0.222  |
| Study design     52.4     47.6     170     0.638       Not declared     60.0     40.0     10     0       Data collection method <td>General population/Patients</td> <td>48.4</td> <td>51.6</td> <td>93</td> <td></td>  | General population/Patients                    | 48.4       | 51.6           | 93       |        |
| Declared52.447.61700.638Not declared60.040.010Data collection methodDeclared89.547.51620.803Not declared55.644.418Obtainment of informed consent </td <td>Study design</td> <td></td> <td></td> <td></td> <td></td>   | Study design                                   |            |                |          |        |
| Not declared60.040.010Data collection method89.547.51620.803Declared89.547.51620.803Not declared55.644.41818Obtainment of informed consent100.349Declared50.050.01100.349Not declared57.142.97020Approval of ethics committee3120.58Declared63.236.85721Pharmacology branch contribution53.846.2390.883Absent52.547.5139390.883   | Declared                                       | 52.4       | 47.6           | 170      | 0.638  |
| Data collection method     89.5     47.5     162     0.803       Not declared     55.6     44.4     18     162     0.803       Obtainment of informed consent     55.6     44.4     18     10     0.349       Declared     50.0     50.0     110     0.349     0.349       Not declared     57.1     42.9     70     10     0.349       Approval of ethics committee     57.1     42.9     70     10     0.349       Declared     63.2     36.8     57     123     0.58     0.58     0.58     0.58     0.58     0.58     0.58     0.57     123     0.58     0.58     0.57     139     0.883     0.59     0.883     0.59     0.883     0.58     0.55     0.55     139     0.583     0.55     0.55     0.59     0.59     0.583     0.59     0.583     0.59     0.583     0.55     0.55     0.55     0.55     0.59     0.55     0.55     0.55     0.55     0.55     0.55   | Not declared                                   | 60.0       | 40.0           | 10       |        |
| Declared     89.5     47.5     162     0.803       Not declared     55.6     44.4     18  | Data collection method                         |            |                |          |        |
| Not declared55.644.418Obtainment of informed consentDeclared50.050.01100.349Not declared57.142.970Approval of ethics committee </td <td>Declared</td> <td>89.5</td> <td>47.5</td> <td>162</td> <td>0.803</td>   | Declared                                       | 89.5       | 47.5           | 162      | 0.803  |
| Obtainment of informed consent50.050.01100.349Declared50.050.01100.349Not declared57.142.97070Approval of ethics committee707070Declared48.052.01230.58Not declared63.236.85770Pharmacology branch contribution717070Present53.846.2390.883Absent52.547.513970  | Not declared                                   | 55.6       | 44.4           | 18       |        |
| Declared     50.0     50.0     110     0.349       Not declared     57.1     42.9     70       Approval of ethics committee          Declared     48.0     52.0     123     0.58       Not declared     63.2     36.8     57        Pharmacology branch contribution            Present     53.8     46.2     39     0.883         Absent     52.5     47.5     139   | Obtainment of informed consent                 |            |                |          |        |
| Not declared57.142.970Approval of ethics committeeDeclaredNot declaredNot declared63.270Pharmacology branch contributionPresent53.846.2390.883Absent52.547.5139   | Declared                                       | 50.0       | 50.0           | 110      | 0.349  |
| Approval of ethics committeeDeclared48.052.01230.58Not declared63.236.857Pharmacology branch contribution777Present53.846.2390.883Absent52.547.5139   | Not declared                                   | 57.1       | 42.9           | 70       |        |
| Declared     48.0     52.0     123     0.58       Not declared     63.2     36.8     57       Pharmacology branch contribution     53.8     46.2     39     0.883       Absent     52.5     47.5     139     0.58   | Approval of ethics committee                   |            |                |          |        |
| Not declared     63.2     36.8     57       Pharmacology branch contribution     53.8     46.2     39     0.883       Present     52.5     47.5     139   | Declared                                       | 48.0       | 52.0           | 123      | 0.58   |
| Pharmacology branch contribution     53.8     46.2     39     0.883       Absent     52.5     47.5     139  | Not declared                                   | 63.2       | 36.8           | 57       |        |
| Present     53.8     46.2     39     0.883       Absent     52.5     47.5     139   | Pharmacology branch contribution               |            |                |          |        |
| Absent 52.5 47.5 139  | Present  | 53.8       | 46.2           | 39       | 0.883  |
|   | Absent   | 52.5       | 47.5           | 139      |        |

SCIE: Science citation index-expanded

# DISCUSSION

In this study, we examined 180 survey-based DUS performed in the last 30 years in Turkiye and observed a number of unfavorable findings, especially about reporting of their key methodological characteristics. These include lack of response rate and/or obtainment of informed consent in around half of the studies, lack of age and/or gender information near one-third, and lack of location and/or data collection method in ten percent. This was remarkable as the majority of the papers were published in journals within the WoS platform and SCIE coverage. In terms of the medications focused on, a significant portion of them addressed antibiotics, much like non-survey-based studies on medication use conducted in Turkiye [3].

Inattentive conduct of the design and analysis of DUS bring along various criticisms, limitations, and quality issues. Despite occasional occurrence of such shortcomings, surveys and questionnaires are still used as important tools in DUS because they can reflect real-life data and provide irreplaceable information about participants' knowledge and attitudes [14–16]. Survey and questionnaire studies, often tending to focus more on local characteristics, may have relatively less universal appeal compared to other types of research [6]. However, surveys conducted in the field of health, by being able to focus on emerging local features, can serve as fundamental sources to better understand health issues, habits, and particularly the knowledge and attitudes of participants regarding medication use in specific communities or regions [16-18]. The overwhelming majority of the publications examined in this study, with academically prestigious attributes such as being on the WoS platform (92%) and more than half being indexed in SCIE, suggest that DUS conducted in Turkiye attract universal interest and, implying their authentic value within health research. The results of survey studies in a country like Turkiye, which has a current population of about 85 million people and provides the opportunity to compare the findings with many other populations, may also be a contributing factor in this global interest. On the other hand, if the shortcomings of these studies are overcome in the future, they could serve as a more functional and appealing resource for the effective and appropriate development of health policies and treatment approaches.

One of the positive findings obtained in the study is the continuous increasing trend in DUS, particularly in recent years. The general upward trend in the number of scientific publications in the country, especially in the field of health, is likely applicable to these studies as well [19]. Additionally, this trend could also be attributed to the advantages of conducting surveys, especially online, in the past decades and the increasing interest in scientific data obtained through surveys and questionnaires regarding rational drug use [3, 20].

Comparing the simultaneous examination of different medications to focusing on a single medication/ medication group, the latter approach in DUS often offer advantages in analysis, interpretation, and presentation [21-23]. Studies related to medication classes that are controversial on their effects, adverse effects. and usage patterns can receive more attention. For instance, antibiotics have emerged as the most compelling medication class globally in recent decades, triggering extensive discussions [24, 25]. In this context, our study reveals that research on individual medications/ medication groups, particularly antibiotics, tends to be published in more qualified journals and receive universal recognition compared to studies covering multiple medications. The prominence of antibiotics is further evident in our findings, as they are the most frequently mentioned drug class among the keywords. This observation aligns with the increasing global significance of antibiotic use and its associated consequences in both our country and worldwide [26-28].

The target population that a survey study examines faces various challenges in accurately representing the entire country [29]. Despite these challenges, interestingly, in our study, it seems valuable at first glance that more than a quarter of the publications declare being conducted nationwide in Turkiye to address this deficiency. However, upon closer inspection of the methodology, it is evident that the studies fall short of meeting this expectation. This indication of a methodological deficiency highlights that researchers and evaluators of these studies may not have adequately considered the ability of the data to represent the entire country. On the other hand, when examined on a provincial level, it was observed that the majority of studies were conducted in Istanbul (15%) and Ankara (8%), in parallel with the size of their populations. Similar findings in relation to drug usage were also reported in another study in Turkiye [3]. However, when the studies were examined in proportion to the population, the fact that the highest number of publications was in Samsun could not be attributed to a specific reason related to this province. This province was followed by Ankara (2.8/

million people) and Izmir (2.7/million people). This situation could be associated with the higher number of universities and educational hospitals in these two provinces compared to other provinces (excluding Istanbul). It could be considered that the excessive population density of Istanbul, Turkiye's largest metropolis, might have caused this province to fall behind in the population-adjusted publication ranking [30].

Obtaining up-to-date information through surveys and questionnaires is possible in a short time, and it is expected to be quickly shared with its audience [6]. In the literature, it has been reported that other non-survey drug use studies in Turkiye are published within an average of 3 years [3]. While the relatively shorter duration for survey studies (2.5 years) is favorable, considering the increasing expectation of recent data to the readers, exploring ways to further shorten this duration in the future might be necessary.

While it is expected that studies are more frequently conducted in healthcare centers, evaluating this situation along with information on who participated in the survey can provide a better interpretation. For instance, the objectivity of responses from patients in a healthcare center may differ from the responses given by healthcare professionals in the same centers [6]. Considering that these surveys are conducted more frequently among healthcare professionals compared to other populations (48.6%), the preference for healthcare centers as the study environment (59.4%) might explain the choice of assessing the prescribing habits of physicians in DUS [3, 8]. The share of patient surveys as less than a quarter of DUS suggests the need for more studies to reveal the knowledge and attitudes of patients regarding medication use in Turkiye. Among the preferred study environments, remote access, ranking second after healthcare centers (12.8%), can be explained by the increasing use of the internet in modern times and the various conveniences it provides for conducting survey methods [20]. On the other hand, increasing use of such surveys could bring along challenges related to data protection, security, privacy management, and visualization of complex questions are expected to become more prominent in health-related research. It is anticipated that the development of specialized tools will be necessary [31].

The insufficient knowledge of the sociodemographic characteristics of the individuals surveyed is a significant factor that compels the accurate evaluation of the data [32]. In a significant portion of the publications examined in our study, the absence of age (27%) and gender (17%) information can be considered important deficiencies, hindering the accurate evaluation of research data. In the literature, there are various findings and interpretations suggesting that women seek health services more frequently and use more medication in DUS [33, 34]. In our analyses involving survey studies that include both genders, the majority of participants were found to be women (70%), consistent with findings in the literature.

In survey and questionnaire studies, the response rate is a key finding for assessing selection bias [35]. In more than half of the examined publications, there is no statement regarding the participants' response rate, which can be considered a prominent deficiency in survey-based DUS in Turkiye. The issue appears to become further worse and complicates accurate analysis, considering the lack of reporting of obtainment of informed consent in nearly half of the studies. Additionally, the disclosure of the response rate has a positive impact on the quality indicators of the publication, as highlighted in our analysis. Accordingly, articles that disclosed the response rate (%66.7) were more likely to be indexed in the SCIE compared to those that did not (%41.4). We observed a similar positive effect in association with publications that included a sponsorship statement.

It is observed that the utilization of concrete scales related to the rationality of drug use is quite low in the examined articles (7.8%) [36]. However, the concept of 'rationality' is encountered more frequently than expected among the declared keywords in the publications. This suggests that, despite authors finding the concept of rationality interesting, they often fail to adequately examine the measurable aspect of the subject in their studies. This can be partly explained by the lower-than-expected contribution of the pharmacology discipline in the articles. This finding indicates the necessity for greater participation of pharmacologists in these studies, who are assumed to be more knowledgeable about evaluations related to the rationality of drug use [37, 38].

The abundance of authorship in scientific publications is a controversial issue. Various developments, such as increased collaborations between different centers and individuals in research topics, advancements in technology, and the requirements of interdisciplinary communication, have led to a gradual increase in the number of authors in articles compared to the past [20]. Beyond the numerical value, it can be argued that the active contribution of authors to the study, their fair representation in the published work, may be more important than the quantity of authors, which could positively impact the quality of a publication [39, 40]. In our study, having more than four authors has a positive impact on the quality of publications, supporting a favorable approach to publications with a relatively larger number of authors.

Our findings should be interpreted with their limitations. The first potential limitation could be about the declared keywords in identifying articles. While we identified the articles to be included in the study through search engines with the use of keywords, those articles that may have conducted a survey on medication use but did not specify appropriate keywords might have been excluded from our analysis. Our inability to examine survey/questionnaire-based DUS that were not digitally accessible is another limitation. In our study, the focus was primarily on the methodological characteristics and format information of the articles. Due to the diverse nature of the medication-focused content in the publications, detailed analyses specific to medications/medication groups were not extensively included in our study to avoid complicating the interpretation of the findings further. This approach can be considered another limitation of the study.

#### Conclusion

In recent years, the majority of survey and questionnaire-based DUS, which have been increasingly conducted, particularly in prestigious journals, indicate that such studies conducted in Turkiye attract universal attention and hold a valuable position in health-related research. Focusing on a specific medication/medication group in DUS is considered a positive attribute for an article, and the preference for conducting DUS through survey and questionnaire methods has been observed to provide researchers with opportunities to shorten the time to publication. Additionally, the careful design of comprehensive surveys and questionnaires, complete recording of demographic data, achieving higher response rates, and the publication of studies that represent diverse populations well are crucial for improving the quality and methodology of DUS in Turkiye. The comparably low contribution of pharmacologists can be considered another important area for the development of DUS. Addressing these needs can serve the purpose of DUS producing more reliable results and serving as a guide for stakeholders in the effective management of healthcare services and resources.

**Ethics Committee Approval:** The Istanbul Medipol University Non-interventional Clinical Research Ethics Committee granted approval for this study (date: 11.05.2023, number: 429).

Authorship Contributions: Concept – AA, VA; Design – AA, VA; Supervision – AA, VA; Fundings – AA; Data collection and/or processing – DH, BC, OG, NH; Analysis and/or interpretation – VA, AA, OG; Literature review – OG, NH, BC, DH; Writing – OG, BC, NH, DH; Critical review – AA, VA.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Use of AI for Writing Assistance:** No artificial intelligence (AI) or assisted technologies (such as Large Language Models [LLMs], chatbots, or image creators) was used in the production of this work.

**Financial Disclosure:** The authors declared that this study has received no financial support.

Peer-review: Externally peer-reviewed.

# REFERENCES

- 1. Bergman U. The history of the drug Utilization Research Group in Europe. Pharmacoepidemiol Drug Saf 2006;15:95–8. [CrossRef]
- Wettermark B, Elseviers M, Almarsdóttir AB, Andersen M, Benko R, Bennie M, et al. Introduction to drug utilization research. In: Elseviers M, Wettermark B, Almarsdóttir AB, Andersen M, Benko R, editors. Drug Utilization Research: Methods and Applications. 1<sup>st</sup> ed. England: Wiley;2016. p. 3–14. [CrossRef]
- Akici A, Havyarimana D, Direnc E, Aydin V. Drug utilization studies in Turkey: a systematic review. North Clin Istanb 2024;11:10–7. [CrossRef]
- Shalini S, Ravichandran V, Saraswathi R, Mohanty BK, Dhanaraj SK. Drug utilization studies-an overview. Int J Pharm Sci Nanotech 2010;3:803-10. [CrossRef]
- Sacristén JA, Soto J. Drug utilization studies as tools in health economics. Pharmacoeconomics 1994;5:299–312. [CrossRef]
- Arikan R. A generale review on interview techniques. [Article in Turkish]. Haliç Üni Sos Bilim Derg 2018;1:97–59.
- Steinke DT. Essentials of pharmacoepidemiology. In: Thomas D, editor. Clinical Pharmacy Education, Practice and Research. Amsterdam: Elsevier BV; 2019. p. 203–14. [CrossRef]
- 8. Bozdemir E, Filiz M. Rational medicine use in Turkey with the knowledge and attitudes towards systematic review of studies determination of behavior. [Article in Turkish]. Dicle Üni Sos Bilim Enst Derg 2021;13:92–105.
- 9. Budakoğlu II, Coşkun Ö, Kıyak YS, Uluoğlu C. Teaching rational prescribing in undergraduate medical education: a systematic search and review. Eur J Clin Pharmacol 2023;79:341–8. [CrossRef]
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Reprint--preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 2009;89:873–80. [CrossRef]
- World Health Organization. World Health Organization Model List of Essential Medicines. 22<sup>nd</sup> List. Geneva: World Health Organization; 2021.
- 12. Turkish Health Ministry. Türkiye İlaç Pazarı Gözlem Raporu-8. Satış Hacmi ve Değeri Açısından 2020 Yılı Pazar Durumu. Ankara: Turkish Drug and Medical Devices Institute (TİTCK); 2021.
- Turkish Statistical Institute. The Results of Address Based Population Registration System, 2021. Available at: https://data.tuik.gov.tr/ Bulten/Index?P=The-Results-of-Address-Based-Population-Registration-System-2021-45500&dil=2#:~:Text=According%20to%20

the%20results%20of,Of%20this%20population%20were%20females. Accessed Jun 6, 2023.

- 14. Oğur R, Tekbaş ÖF. Anket nasıl hazırlanır? Sted 2003;12:336–40.
- Korn EL, Graubard BI. Analysis of Health Surveys. New York: John Wiley & Sons; 2011.
- Gama H, Correia S, Lunet N. Questionnaire design and the recall of pharmacological treatments: a systematic review. Pharmacoepidemiol Drug Saf 2009;18:175–87. [CrossRef]
- 17. Håkonsen H, Hange D, Hedenrud T. Intra-individual variability in self-reported use of non-steroidal anti-inflammatory and analgesic medicines depending on mode of data collection - observations from the population study of women in Gothenburg, Sweden. Int J Gen Med 2021;14:3243–50. [CrossRef]
- 18. Gama H. Drug utilization studies. Arq Med 2008;22:69-74. [CrossRef]
- Al U, Sezen U, Soydal İ. The evaluation of scientific publications of Hacettepe University using social network analysis method. [Article in Turkish]. Hacettepe Uni J Fac Letters 2012;29:53–71.
- Eysenbach G, Wyatt J. Using the internet for surveys and health research. J Med Internet Res 2002;4:e13. [CrossRef]
- Klungel OH, de Boer A, Paes AHP, Herings RMC, Seidell JC, Bakker A. Influence of question structure on the recall of self-reported drug use. J Clin Epidemiol 2000;53:273–7. [CrossRef]
- Gmel G. Änderungen in der abfolge von fragen zur medikamenteneinnahme im schweizer gesundheitssurvey-gibt es effekte für die prävalenzschätzungen? Soz-Präventivmedizin 1999;44:126–36. [CrossRef]
- Mitchell AA, Cottler LB, Shapiro S. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 1986;123:670– 6. [CrossRef]
- Auta A, Hadi MA, Oga E, Adewuyi EO, Abdu-Aguye SN, Adeloye D, et al. Global access to antibiotics without prescription in community pharmacies: a systematic review and meta-analysis. J Infect 2019;78:8– 18. [CrossRef]
- Ferri M, Ranucci E, Romagnoli P, Giaccone V. Antimicrobial resistance: a global emerging threat to public health systems. Crit Rev Food Sci Nutr 2017;57:2857–76. [CrossRef]
- Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Pan Am J Public Health 2010;27:219–2. [CrossRef]
- 27. Karabay O, Hosoglu S. Increased antimicrobial consumption following reimbursement reform in Turkey. J Antimicrob Chemother

2008;61:1169-71. [CrossRef]

- 28. Bachhav SS, Kshirsagar NA. Systematic review of drug utilization studies & the use of the drug classification system in the WHO-SEA-RO Region. Indian J Med Res 2015;142:120–9. [CrossRef]
- 29. Lund B. The questionnaire method in systems research: an overview of sample sizes, response rates and statistical approaches utilized in studies. VINE J Inf Knowl Manag Syst 2021;53:1–10. [CrossRef]
- Mammadov R, Aypay A. Efficiency analysis of research universities in Turkey. Int J Educ Dev 2020;75:102176. [CrossRef]
- Benítez JA, Labra JE, Quiroga E, Martín V, García I, Marqués-Sánchez P, et al. A web-based tool for automatic data collection, curation, and visualization of complex healthcare survey studies including social network analysis. Comput Math Methods Med 2017;2017:2579848. [CrossRef]
- Story DA, Tait AR. Survey research. Anesthesiology 2019;130:192– 202. [CrossRef]
- 33. Orlando V, Mucherino S, Guarino I, Guerriero F, Trama U, Menditto E. Gender differences in medication use: a drug utilization study based on real world data. Int J Environ Res Public Health 2020;17:3926. [CrossRef]
- 34. Fernández-Liz E, Modamio P, Catalán A, Lastra CF, Rodríguez T, Mariño EL. Identifying how age and gender influence prescription drug use in a primary health care environment in Catalonia, Spain. Br J Clin Pharmacol 2008;65:407–17. [CrossRef]
- 35. Barclay S. Not another questionnaire! Maximizing the response rate, predicting non-response and assessing non-response bias in postal questionnaire studies of GPs. Fam Pract 2002;19:105–11. [CrossRef]
- World Health Organization. How to investigate drug use in health facilities: selected drug use indicators. Available at: https://apps.who.int/ iris/handle/10665/60519. Accessed Jul 14, 2023.
- Sjöqvist F. Development of clinical pharmacology as a medical speciality in Europe - the roles of WHO, IUPHAR and EACPT. Basic Clin Pharmacol Toxicol 2014;115:172–8. [CrossRef]
- Gulmez SE, Aydin V, Akici A. Footprints of clinical pharmacology in Turkey: past, present, and future. Clin Ther 2020;42:351–62. [CrossRef]
- Waltman L, vanEck NJ. Field-normalized citation impact indicators and the choice of an appropriate counting method. J Informetrics 2015;9:872–94. [CrossRef]
- 40. Töreci K. Publication ethic. [Article in Turkish]. Akad Gida Derg 2005;3:24–44.